Proteomic characterisation of polyglucosan bodies in skeletal muscle in RBCK1 deficiency
- PMID: 34405429
- DOI: 10.1111/nan.12761
Proteomic characterisation of polyglucosan bodies in skeletal muscle in RBCK1 deficiency
Abstract
Aims: Several neurodegenerative and neuromuscular disorders are characterised by storage of polyglucosan, consisting of proteins and amylopectin-like polysaccharides, which are less branched than in normal glycogen. Such diseases include Lafora disease, branching enzyme deficiency, glycogenin-1 deficiency, polyglucosan body myopathy type 1 (PGBM1) due to RBCK1 deficiency and others. The protein composition of polyglucosan bodies is largely unknown.
Methods: We combined quantitative mass spectrometry, immunohistochemical and western blot analyses to identify the principal protein components of polyglucosan bodies in PGBM1. Histologically stained tissue sections of skeletal muscle from four patients were used to isolate polyglucosan deposits and control regions by laser microdissection. Prior to mass spectrometry, samples were labelled with tandem mass tags that enable quantitative comparison and multiplexed analysis of dissected samples. To study the distribution and expression of the accumulated proteins, immunohistochemical and western blot analyses were performed.
Results: Accumulated proteins were mainly components of glycogen metabolism and protein quality control pathways. The majority of fibres showed depletion of glycogen and redistribution of key enzymes of glycogen metabolism to the polyglucosan bodies. The polyglucosan bodies also showed accumulation of proteins involved in the ubiquitin-proteasome and autophagocytosis systems and protein chaperones.
Conclusions: The sequestration of key enzymes of glycogen metabolism to the polyglucosan bodies may explain the glycogen depletion in the fibres and muscle function impairment. The accumulation of components of the protein quality control systems and other proteins frequently found in protein aggregate disorders indicates that protein aggregation may be an essential part of the pathobiology of polyglucosan storage.
Keywords: glycogen metabolism; glycogen storage disease; polyglucosan; protein aggregation.
© 2021 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.
Similar articles
-
Glycogen synthase downregulation rescues the amylopectinosis of murine RBCK1 deficiency.Brain. 2022 Jul 29;145(7):2361-2377. doi: 10.1093/brain/awac017. Brain. 2022. PMID: 35084461 Free PMC article.
-
Proteomic profiling of polyglucosan bodies associated with glycogenin-1 deficiency in skeletal muscle.Neuropathol Appl Neurobiol. 2024 Jun;50(3):e12995. doi: 10.1111/nan.12995. Neuropathol Appl Neurobiol. 2024. PMID: 38923610
-
Polyglucosan storage myopathies.Mol Aspects Med. 2015 Dec;46:85-100. doi: 10.1016/j.mam.2015.08.006. Epub 2015 Aug 13. Mol Aspects Med. 2015. PMID: 26278982 Review.
-
Myofiber-type-dependent 'boulder' or 'multitudinous pebble' formations across distinct amylopectinoses.Acta Neuropathol. 2024 Feb 27;147(1):46. doi: 10.1007/s00401-024-02698-x. Acta Neuropathol. 2024. PMID: 38411740
-
RBCK1-related disease: A rare multisystem disorder with polyglucosan storage, auto-inflammation, recurrent infections, skeletal, and cardiac myopathy-Four additional patients and a review of the current literature.J Inherit Metab Dis. 2020 Sep;43(5):1002-1013. doi: 10.1002/jimd.12234. Epub 2020 Apr 16. J Inherit Metab Dis. 2020. PMID: 32187699 Review.
Cited by
-
Proteomic Profiling Towards a Better Understanding of Genetic Based Muscular Diseases: The Current Picture and a Look to the Future.Biomolecules. 2025 Jan 15;15(1):130. doi: 10.3390/biom15010130. Biomolecules. 2025. PMID: 39858524 Free PMC article. Review.
-
LUBAC: a new player in polyglucosan body disease.Biochem Soc Trans. 2021 Nov 1;49(5):2443-2454. doi: 10.1042/BST20210838. Biochem Soc Trans. 2021. PMID: 34709403 Free PMC article. Review.
-
A novel likely pathogenic homozygous RBCK1 variant in dilated cardiomyopathy with muscle weakness.ESC Heart Fail. 2024 Jun;11(3):1472-1482. doi: 10.1002/ehf2.14702. Epub 2024 Feb 8. ESC Heart Fail. 2024. PMID: 38329383 Free PMC article.
-
Glycogen synthase downregulation rescues the amylopectinosis of murine RBCK1 deficiency.Brain. 2022 Jul 29;145(7):2361-2377. doi: 10.1093/brain/awac017. Brain. 2022. PMID: 35084461 Free PMC article.
-
Pathomorphogenesis of Glycogen-Ground Glass Hepatocytic Inclusions (Polyglucosan Bodies) in Children after Liver Transplantation.Int J Mol Sci. 2022 Sep 2;23(17):9996. doi: 10.3390/ijms23179996. Int J Mol Sci. 2022. PMID: 36077394 Free PMC article.
References
REFERENCES
-
- Robitaille Y, Carpenter S, Karpati G, DiMauro SD. A distinct form of adult polyglucosan body disease with massive involvement of central and peripheral neuronal processes and astrocytes: a report of four cases and a review of the occurrence of polyglucosan bodies in other conditions such as Lafora's disease and normal ageing. Brain. 1980;103:315-336.
-
- Cavanagh JB. Corpora-amylacea and the family of polyglucosan diseases. Brain Res Rev. 1999;29(2-3):265-295.
-
- Hedberg-Oldfors C, Abramsson A, Osborn DPS, et al. Cardiomyopathy with lethal arrhythmias associated with inactivation of KLHL24. Hum Mol Genet. 2019;28(11):1919-1929.
-
- Hedberg-Oldfors C, Oldfors A. Polyglucosan storage myopathies. Mol Aspects Med. 2015;46:85-100.
-
- Kilimann MW, Oldfors A. Glycogen pathways in disease: new developments in a classical field of medical genetics. J Inherit Metab Dis. 2015;38(3):483-487.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources